N | Women | N | Men | |
---|---|---|---|---|
Cases/no. of patients | HR (95% CI) | Cases/no. of patients | HR (95% CI) | |
Overall | ||||
Years 1–2 | 4579/11963 | 1.13 (1.06 to 1.20) | 4457/11515 | 1.27 (1.20 to 1.35) |
Years 3–5 | 1237/6270 | 0.87 (0.77 to 0.97) | 1437/5960 | 0.95 (0.85 to 1.05) |
Adjusted for ASA score | ||||
Years 1–2 | 3924/10787 | 1.15 (1.08 to 1.23) | 3852/10439 | 1.27 (1.19 to 1.35) |
Years 3–5 | 1127/5811 | 0.86 (0.76 to 0.97) | 1318/5550 | 0.94 (0.84 to 1.05) |
Adjusted for no. of harvested lymph nodes | ||||
Years 1–2 | 3280/10192 | 1.42 (1.32 to 1.52) | 3152/9703 | 1.57 (1.47 to 1.69) |
Years 3–5 | 1121/5889 | 0.91 (0.81 to 1.03) | 1296/5562 | 1.02 (0.91 to 1.15) |
Adjusted for no. of lymph nodes with metastases | ||||
Years 1–2 | 2913/9741 | 1.16 (1.07 to 1.25) | 2782/9253 | 1.30 (1.20 to 1.40) |
Years 3–5 | 1103/5805 | 0.86 (0.76 to 0.97) | 1275/5490 | 0.98 (0.88 to 1.10) |
Adjusted for presence of distant metastases | ||||
Years 1–2 | 4365/11591 | 1.22 (1.15 to 1.29) | 4293/11195 | 1.35 (1.27 to 1.43) |
Years 3–5 | 1193/6087 | 0.92 (0.82 to 1.04) | 1402/5813 | 1.03 (0.92 to 1.14) |
Adjusted for UICC stage | ||||
Years 1–2 | 4176/11296 | 1.18 (1.10 to 1.25) | 4137/10917 | 1.31 (1.24 to 1.40) |
Years 3–5 | 1185/6043 | 0.87 (0.78 to 0.99) | 1377/5736 | 0.99 (0.89 to 1.11) |
Global model | 2649/9106 | 1.28 (1.18 to 1.39) | 2549/8674 | 1.36 (1.25 to 1.47) |
1036/5473 | 0.93 (0.82 to 1.06) | 1194/5175 | 1.06 (0.94 to 1.19) | |
Unadjusted on data with complete conf. info. | 2649/9106 | 1.29 (1.19 to 1.40) | 2549/8674 | 1.34 (1.24 to 1.45) |
1036/5473 | 0.87 (0.77 to 0.98) | 1194/5175 | 0.97 (0.86 to 1.09) |
Cox proportional hazard models adjusted for age with additional adjustment for the mentioned factors one by one.
Categories used in the adjusted analysis: ASA scores 1, 2, 3, 4; harvested lymph nodes 0, 1–3, 4 and more; distant metastases yes, no, value unknown; UICC stages I, II, III, IV.